TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.

NCT Number	NCT07279402
Lead Sponsor	Antalya Training and Research Hospital Collaborators: Hoffmann-La Roche
Conditions	NSCLC Stage IV, PD-L1 Gene Mutation, Atezolizumab, Real World Study
Enrollment	150 participants
Start Date	2025-09-15
Primary Completion	2027-05-01 (estimated)
Study Completion	2027-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-30